Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization to Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals' liver ...
Shares of Madrigal Pharmaceuticals (MDGL) traded sharply higher for the second straight session on Wednesday after Cantor Fitzgerald upgraded the company, arguing that the commercial rollout of its ...
CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. It’s FDA-approved drug, Rezdiffra ...
24/7 Wall St. on MSN
3 biotech stocks to watch for respectable growth beyond AI
Quick Read Cytokinetics launched FDA-approved MYQORZO in December 2025 with Q4 revenue of $17.75M beating consensus by 121%; ...
Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. shares increased following ...
Madrigal Pharmaceuticals MDGL reported third-quarter 2025 loss of $5.08 per share, wider than the Zacks Consensus Estimate of a loss of $1.98. In the year-ago quarter, the company had incurred a loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results